HugoScore hugoscore.org

Mental health AI

Therabot

Therabot is assessed here as a supervised research deployment. Trial participation and researcher oversight do not establish the controls of a current commercial product. Its former 45 is retained as history, outside current consumer-score comparisons.

Checklist assessment dated October 30, 2026. Independent confirmation is incomplete. Hugo has not personally verified this service.

Not assessedDocument-based draft. Independent confirmation incomplete; not product-tested.How categories work

Agency checklist

Not assessed

Supervised research deployment; not available as an ordinary patient service.

This is not a zero score or an adverse agency finding.

Earlier v1.3 assessment and control finding

Historical assessment under different rules. It does not set the current checklist zone.

Not enough evidenceEarlier review, before the published method. Documents only.

Agency finding, before method v1.3

Research-stage, unclear in deployment

Legacy editorial placement, pre-method: 45

This profile has not yet been reviewed under the published method. Its finding and any number are editorial placements made before the method existed.

Evidence
Documentary review. Public sources only, no hands-on testing by HugoScore.
Review status
AI draft. No person has settled the findings.
The question we ask Who does Therabot serve in this deployment?
Control Therabot supervised research deployment in Dartmouth's randomized trial (NCT06013137, NEJM AI 2025) and related studies. Not an assumed current commercial therapy product.
Agency read Not assessed
Vendor
Dartmouth College (Jacobson AI and Mental Health Lab, Center for Technology and Behavioral Health); spinout Therabot Labs, LLC
Who it serves
Supervised research AI
Primary User
Research participants within a supervised study
Control Model
Researcher-governed study deployment. Current commercial controls not established.
Patient Impact
Symptom improvement and therapeutic alliance do not themselves demonstrate patients becoming better able to interrogate advice, evaluate evidence or redirect therapeutic goals.
Profile Status
Not assessed
Last assessed
Oct 30, 2026
Earlier review confidence
Moderate for historical trial deployment, low for present commercialization (AI-assisted draft)
Earlier review model
OpenAI Codex / GPT-6
Earlier human review record
Hugo Campos authorized publication of these AI-assisted draft reassessments on September 8, 2026. This does not claim comprehensive human verification of every finding.

Earlier evidence and assessment

The sections below preserve the earlier review. Its classifications and provenance are historical; the checklist above gives the current draft classification.

Earlier finding · Legacy editorial placement, pre-method: 45

Method v1.3. The control line is evidence for how the agency finding arose, not a quality score. Legacy editorial placement, pre-method: 45. Not comparable with v1.3 positions.

Research-stage, unclear in deployment

Therabot is assessed here as a supervised research deployment. Trial participation and researcher oversight do not establish the controls of a current commercial product. Its former 45 is retained as history, outside current consumer-score comparisons.

Patient agency

How this tool changes agency

Expands agency when

Symptom improvement and therapeutic alliance do not themselves demonstrate patients becoming better able to interrogate advice, evaluate evidence or redirect therapeutic goals.

Limits agency when

Public commercial availability and governance are not established by the bounded institutional-source pass

Patient agency assessment

Who sets and changes the goal?

Patient authority

Participants could initiate conversations inside a researcher-governed intervention. Enrollment restrictions are a research scope boundary, not evidence of coercion or diminished agency within participation.

What can the patient understand, question, or do?

Critical capacity

Symptom improvement and therapeutic alliance do not themselves demonstrate patients becoming better able to interrogate advice, evaluate evidence or redirect therapeutic goals.

Can the patient evaluate the conditions of use?

Informed control

Supervision is documented for the trial. Future commercial privacy, withdrawal, correction and oversight cannot be inferred from research safeguards.

Text findings

Conditions of use

Published controls and their limits

Supervision is documented for the trial. Future commercial privacy, withdrawal, correction and oversight cannot be inferred from research safeguards.

What remains unknown?

Not tested or not established

Public commercial availability and governance are not established by the bounded institutional-source pass

Who evaluated this?

AI-assisted public-source draft

Vendor statements describe published conditions, not independently verified behavior. No clinical, security, accessibility, or legal validation is claimed. Earlier evidence remains dated in the report and history.

Sources checked

Source-specific findings and retrieval limitations are recorded in the full report.

Earlier review provenance

Criteria

CAIHL-derived HugoScore framework and September 7 qualitative review priorities. Draft v1.2 numerical anchors remain unadopted.

Reviewer

AI-assisted public-source reassessment prepared in OpenAI Codex.

AI / model

OpenAI Codex / GPT-6

Human review

Hugo Campos authorized publication of these AI-assisted draft reassessments on September 8, 2026. This does not claim comprehensive human verification of every finding.

Review date

2026-09-08

Limitations

Public commercial availability and governance are not established by the bounded institutional-source pass No live product use, patient-data upload, account creation, code audit, clinical evaluation, or independent implementation validation.

Earlier review method

Focused public-source reassessment using CAIHL: patient authority, critical capacity, and informed control. Existing evidence plus one focused primary-source pass and at most one targeted follow-up. No live product testing. Numerical scores remain provisional editorial placements, not a new calculation.

Not assessed · Moderate for historical trial deployment, low for present commercialization (AI-assisted draft)